Parasite

SLU-10906 is a potent inhibitor targeting the protozoan parasite Cryptosporidium. Demonstrating significant efficacy in a cell-based infection model with an EC50 of 0.19 μM, SLU-10906 is non-cytotoxic, making it a valuable tool for investigating cryptosporidiosis. Its oral bioavailability further enhances its potential for preclinical studies and therapeutic exploration.

Carbonic anhydrase inhibitor 27 is a targeted antitrypanosomal agent that inhibits carbonic anhydrase activity, impacting parasite viability. This compound effectively reduces parasitic load in the bloodstream and enhances the survival rate of infected murine models. It is valuable for research applications focused on the treatment of parasitic infections such as Trypanosomiasis.

MMV665852 is an antischistosomal agent that targets Schistosoma mansoni, inhibiting worm viability in vitro. This compound has demonstrated efficacy in reducing worm burden in murine models of schistosomiasis, making it a valuable tool for research in parasitic disease treatment and prevention.

TachypleginA-2 is a small-molecule inhibitor that targets parasite motility and invasion. It effectively induces a mobility shift in TgMLC1, an essential light chain involved in cellular movement. This compound is useful for research investigating the mechanisms of parasitic behavior and the development of potential therapeutic strategies against parasitic infections.

Bitipazone is a potent cysteine ester derivative that serves as an effective anticoccidial agent. It demonstrates significant efficacy against coccidian parasites in animal models, including rabbits and turkeys, with good tolerability observed at concentrations below 90 ppm in feed. Pharmacokinetic studies indicate that Bitipazone is slowly eliminated from the blood and organs, making it a valuable compound for research in parasitology and veterinary medicine.

AB 3217-B is a parasite inhibitor that targets mite species with potent anti-mite activity. This compound demonstrates efficacy in disrupting the life cycle of parasites, making it valuable for research related to pest control and parasitology. Its ability to inhibit mite proliferation positions it as a potential candidate for further studies aimed at developing effective treatments against parasitic infestations.

Anti-Trypanosoma cruzi agent-5 is a potent inhibitor of Trypanosoma cruzi, the causative agent of Chagas disease. This compound demonstrates significant antiparasitic activity, inhibiting the proliferation of the parasite in vitro. It is suitable for research applications investigating the mechanisms of Chagas disease and potential therapeutic strategies.

RS 49676 is an N-substituted imidazole compound that acts as a potent inhibitor against endogenous amoebae, displaying an ED50 of less than 0.1 ng/mL. It demonstrates significant biological activity in vivo, notably prolonging the average survival time of mice infected with Trypanosoma cruzi to over 11 weeks when administered at a dose of 100 mg/kg per day via subcutaneous injection. This compound is valuable for research applications involving parasitic infections and host-pathogen interactions.

ML471 is an orally active inhibitor of parasite tyrosyl-tRNA synthetase (PfTyrRS), which is essential for protein synthesis in Plasmodium species. This compound exhibits potent activity against malaria by selectively targeting PfTyrRS, providing valuable insights into the treatment of malaria infections. It is a useful tool for researchers investigating novel antimalarial strategies and exploring the role of tRNA synthetases in parasitic biology.

(Rac)-ACT-451840 is a parasite inhibitor with significant antimalarial properties. It demonstrates effective antimalarial activity against P. berghei-infected mice, achieving an ED90 of 13 mg/kg and showing inhibitory effects at higher doses. In humanized immunodeficient mouse models infected with P. falciparum, the compound has an ED90 of 3.7 mg/kg. (Rac)-ACT-451840 is structurally similar to artemisinin and offers a rapid onset of action, although it necessitates repeated high dosing for optimal efficacy.

WRR-483 is an irreversible cysteine protease inhibitor targeting cruzain, demonstrating potent trypanocidal activity against Trypanosoma cruzi. This compound effectively inhibits the proliferation of the parasite in cell culture and shows significant efficacy in eradicating parasitic infection in acute Chagas disease mouse models. Its pH-dependent high affinity makes WRR-483 a promising candidate for research applications focused on combating Chagas disease.

Albendazole sulfoxide, the principal active metabolite of Albendazole, acts as a potent inhibitor of parasite growth. It demonstrates significant anti-parasitic activity against Echinococcus multilocularis metacestodes, making it valuable in the study of parasitic infections and potential therapeutic interventions. This compound is utilized in research focused on parasitology and drug efficacy against helminthic diseases.

Oxfendazole is a sulfoxide derivative of fenbendazole that targets parasitic organisms through inhibition of energy metabolism. Its primary biological activity is the effective combat against a broad spectrum of parasites. This compound is utilized in research focused on parasitology and can also be studied for its potential effects in tumor promotion investigations.

β-Hederin is a saponin derived from Hedera helix L. (Araliaceae) that demonstrates significant antileishmanial activity. It exhibits IC50 values of 1.5 μM against L. mexicana promastigotes, 68 nM against L. mexicana amastigotes, and 4.57 μM in THP-1 cells. This compound may be utilized in research applications targeting leishmaniasis, providing insights into potential therapeutic strategies against parasitic infections.

Morantel tartrate is an effective anthelmintic agent targeting gastrointestinal parasites. It is primarily utilized in veterinary medicine to control subclinical gastrointestinal parasitism in cattle on pasture. Following administration, morantel tartrate can be detected in ruminal, abomasal, ileal fluids, and feces for up to 98 days, indicating its prolonged activity. This compound is instrumental in research related to parasitic infections and antiparasitic drug development.

SC83288 is an inhibitor of PfDNMT2 in Plasmodium falciparum, with an IC50 of 7 μM. This compound disrupts the epigenetic regulation within malaria parasites, impeding DNA replication and nuclear division, and consequently arrests the development of the asexual blood stage. SC83288 also induces pyknotic morphology in the parasites without impacting cytokinesis post-nuclear division or parasite egress, making it valuable for malaria-related research applications.